Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) have received a consensus rating of “Hold” from the nine research firms that are currently covering the stock. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $128.50.
A number of research analysts have recently weighed in on the stock. Canaccord Genuity set a $145.00 price target on shares of IDEXX Laboratories and gave the company a “buy” rating in a report on Tuesday, February 14th. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $159.00 price target on the stock in a report on Tuesday, February 7th. Finally, Feltl & Co. downgraded shares of IDEXX Laboratories from a “hold” rating to a “sell” rating in a report on Friday, February 3rd.
TRADEMARK VIOLATION NOTICE: This story was first posted by Web Breaking News and is the property of of Web Breaking News. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at http://www.webbreakingnews.com/2017/03/25/idexx-laboratories-inc-idxx-receives-consensus-rating-of-hold-from-brokerages.html.
IDEXX Laboratories (NASDAQ:IDXX) opened at 153.74 on Monday. The company has a market cap of $13.53 billion, a PE ratio of 63.01 and a beta of 0.48. The stock’s 50 day moving average is $146.37 and its 200 day moving average is $122.92. IDEXX Laboratories has a 12 month low of $75.03 and a 12 month high of $154.57.
IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Thursday, February 2nd. The company reported $0.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.51 by $0.07. The business had revenue of $443 million for the quarter, compared to the consensus estimate of $436.07 million. IDEXX Laboratories had a net margin of 12.51% and a negative return on equity of 671.57%. IDEXX Laboratories’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.48 EPS. Equities analysts predict that IDEXX Laboratories will post $2.94 earnings per share for the current year.
In related news, VP Brian P. Mckeon sold 9,924 shares of IDEXX Laboratories stock in a transaction on Wednesday, February 8th. The shares were sold at an average price of $141.64, for a total value of $1,405,635.36. Following the transaction, the vice president now owns 45,235 shares in the company, valued at approximately $6,407,085.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Jonathan W. Ayers sold 36,250 shares of IDEXX Laboratories stock in a transaction on Wednesday, February 8th. The stock was sold at an average price of $141.63, for a total transaction of $5,134,087.50. The disclosure for this sale can be found here. Insiders sold a total of 84,174 shares of company stock worth $11,955,273 in the last quarter. Insiders own 2.79% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in IDXX. MSI Financial Services Inc increased its position in shares of IDEXX Laboratories by 15.2% in the third quarter. MSI Financial Services Inc now owns 964 shares of the company’s stock valued at $109,000 after buying an additional 127 shares during the period. CWM LLC increased its position in shares of IDEXX Laboratories by 941.2% in the third quarter. CWM LLC now owns 1,770 shares of the company’s stock valued at $200,000 after buying an additional 1,600 shares during the period. Hills Bank & Trust Co. purchased a new position in shares of IDEXX Laboratories during the third quarter valued at approximately $210,000. Hartford Investment Management Co. purchased a new position in shares of IDEXX Laboratories during the third quarter valued at approximately $211,000. Finally, First Midwest Bank Trust Division purchased a new position in shares of IDEXX Laboratories during the third quarter valued at approximately $216,000. Hedge funds and other institutional investors own 91.42% of the company’s stock.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.